
Auriga Partners
Description
Auriga Partners is a well-established independent venture capital firm based in Paris, France, founded in 1998. With a strong focus on early-stage investments, the firm primarily targets the Information Technology sector, encompassing areas such as software, internet, telecommunications, semiconductors, and electronics. Their investment thesis extends to cutting-edge domains like deep tech, artificial intelligence, cybersecurity, SaaS, fintech, and the Internet of Things, demonstrating a commitment to innovation across various digital frontiers.
Auriga Partners typically deploys initial investment tickets ranging from €1 million to €5 million (approximately $1.08 million to $5.4 million, based on recent exchange rates). This initial capital is often followed by significant additional funding, potentially reaching up to €10 million per company, supporting portfolio companies through various growth stages. Their approach emphasizes active partnership with founders, leveraging their extensive network and operational expertise to help scale promising technology ventures.
Over its more than two decades of operation, Auriga Partners has built a robust track record, having supported over 80 companies since its inception. The firm has successfully managed multiple funds, with a total funding amount of approximately $191.6 million across four distinct vehicles. This long-standing presence in the European tech ecosystem has enabled them to contribute significantly to the development of numerous innovative companies, leading to a strong history of successful exits and value creation for their limited partners.
Investor Profile
Auriga Partners has backed more than 162 startups, with 0 new investments in the last 12 months alone. The firm has led 32 rounds, about 20% of its total and boasts 40 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series A, Series Unknown rounds (top funding stages).
- Majority of deals are located in France, United States, Switzerland.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
- Typical check size: $1.1M – $5.4M.
Stage Focus
- Series B (28%)
- Series A (23%)
- Series Unknown (16%)
- Series C (13%)
- Series D (5%)
- Post Ipo Equity (4%)
- Seed (3%)
- Series E (3%)
- Private Equity (1%)
- Corporate Round (1%)
Country Focus
- France (65%)
- United States (17%)
- Switzerland (6%)
- United Kingdom (4%)
- Sweden (2%)
- Pakistan (2%)
- Israel (2%)
- Belgium (1%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Manufacturing
- Medical
- Software
- Medical Device
- Therapeutics
- Information Technology
- Enterprise Software
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.